VistaGen Therapeutics, Inc.

Vistagen said it had $61.8 million in cash, cash equivalents and marketable securities as of December 31, 2025, after Shawn Singh corrected an initial mention of $61.2 million. The company did not report revenue, EPS, gross margin, or other operating financial metrics on this call. Management said it implemented company-wide cash preservation measures during the quarter to extend runway and maintain flexibility. For guidance, management said PALISADE-4 is on track with previously given guidance for the randomized portion and that the company plans to submit a U.S. IND for refisolone in the first half of 2026.

Shawn Singh framed the quarter as an important one focused on execution, learning from PALISADE-3, and making disciplined adjustments to PALISADE-4. He emphasized that the company is using the broader PALISADE dataset, including open-label data, to understand placebo and drug response and potentially inform future regulatory discussions with the FDA. He also stressed the unmet need in social anxiety disorder and said Vistagen remains committed to advancing a hormone-free women’s health candidate with a data-driven approach.

Nick Tressler’s main financial comment was a clarification that cash, cash equivalents and marketable securities totaled $61.8 million at December 31, 2025. Management also said the quarter included company-wide cash preservation measures intended to improve operational efficiency, extend runway, and preserve strategic flexibility across the Pherin pipeline. No revenue, expense, or margin figures were discussed on the call, and there was no detailed capital allocation update beyond runway preservation.

Analysts focused heavily on PALISADE-3/4, asking whether individual curves showed separation, whether SAP changes would require FDA alignment, and whether enrollment or the target size would change. Management said only top-line PALISADE-3 data had been publicly released, that SAP changes would require resubmission and FDA alignment before database lock, and that enrollment targets would not change. On regulatory path questions, Shawn Singh said approval would depend on the totality of evidence and weight of evidence across the program, and he declined to speculate on approval scenarios or comment on blinded PALISADE-4 data.